{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:16:58Z","timestamp":1783387018469,"version":"3.54.6"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1245\/s10434-022-12877-3","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T19:02:40Z","timestamp":1671822160000},"page":"1889-1890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases"],"prefix":"10.1245","volume":"30","author":[{"given":"Daryl K. A.","family":"Chia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Jun","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Shabbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy B. Y.","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Peng","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"12877_CR1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11998-z","author":"DKA Chia","year":"2022","unstructured":"Chia DKA, Sundar R, Kim G, et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022. https:\/\/doi.org\/10.1245\/s10434-022-11998-z (PMID: 36070113).","journal-title":"Ann Surg Oncol."},{"key":"12877_CR2","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/bjs\/znab200","volume":"108","author":"PE Bonnot","year":"2021","unstructured":"Bonnot PE, Lintis A, Mercier F, et al. Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). Br J Surg. 2021;108:1225\u201335. https:\/\/doi.org\/10.1093\/bjs\/znab200 (PMID: 34498666).","journal-title":"Br J Surg."},{"key":"12877_CR3","doi-asserted-by":"crossref","unstructured":"Rau, B., Lang, H., K\u00f6nigsrainer A, et al.: The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): a randomized multicentre phase III trial (GASTRIPEC-I-trial). Abstract 13760, Proffered paper session\u2013gastrointestinal tumours, non-colorectal, ESMO Congress (2021)","DOI":"10.1016\/j.annonc.2021.08.1485"},{"key":"12877_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2021","unstructured":"Yoshida K, Yasufuku I, Terashima M, et al. CONVO-GC-1 Study Group, Federation of Asian Clinical Oncology (FACO). International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2021;6:227\u201340. https:\/\/doi.org\/10.1002\/ags3.12515 (PMID: 35261948 PMCID: PMC8889854).","journal-title":"Ann Gastroenterol Surg."},{"key":"12877_CR5","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028\u201340. https:\/\/doi.org\/10.1200\/JCO.18.01688 (PMID: 31084544).","journal-title":"J Clin Oncol."},{"key":"12877_CR6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922\u20139. https:\/\/doi.org\/10.1200\/JCO.2018.77.8613 (PMID: 29746229).","journal-title":"J Clin Oncol."},{"key":"12877_CR7","doi-asserted-by":"publisher","first-page":"20180116","DOI":"10.1515\/pp-2018-0116","volume":"3","author":"C Eveno","year":"2018","unstructured":"Eveno C, Jouvin I, Pocard M. PIPAC EstoK 01: pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study. Pleura Peritoneum. 2018;3:20180116. https:\/\/doi.org\/10.1515\/pp-2018-0116 (PMID: 30911659 PMCID: PMC6405009).","journal-title":"Pleura Peritoneum."},{"key":"12877_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1245\/s10434-020-08739-5","volume":"28","author":"B Badgwell","year":"2021","unstructured":"Badgwell B, Ikoma N, Murphy MB, et al. A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Ann Surg Oncol. 2021;28:258\u201364. https:\/\/doi.org\/10.1245\/s10434-020-08739-5 (PMID: 32556731).","journal-title":"Ann Surg Oncol."},{"key":"12877_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2147\/BTT.S290323","volume":"15","author":"D Basile","year":"2021","unstructured":"Basile D, Simionato F, Cappetta A, et al. State-of-the-art of monoclonal antibodies for the treatment of gastric cancer. Biologics. 2021;15:451\u201362. https:\/\/doi.org\/10.2147\/BTT.S290323 (PMID: 34764633 PMCID: PMC8572727).","journal-title":"Biologics."},{"key":"12877_CR10","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.21.02745","volume":"40","author":"YX Gwee","year":"2022","unstructured":"Gwee YX, Chia DKA, So J, et al. Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis. J Clin Oncol. 2022;40:2830. https:\/\/doi.org\/10.1200\/JCO.21.02745 (PMID: 35649219 PMCID: PMC9390822).","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12877-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12877-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12877-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T21:46:14Z","timestamp":1675892774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12877-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["12877"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12877-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"10 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by the National Medical Research Council (NMRC) Translational and Clinical Flagship Programme (NMRC\/TCR\/009-NUHS\/2013), NMRC Centre Grants (NMRC\/CG\/012\/2013, NMRC\/CG\/M005\/2017_NCIS) and NMRC Open Fund Large Collaborative Grant (OFLCG18May-9923). Dr Raghav Sundar is also supported by a NMRC Fellowships (NMRC\/Fellowship\/0059\/2018 and NMRC\/MOH\/000627).\nTrial registry: NCT01739894.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}